Early vascular aging (EVA): consequences and prevention
Author:
Open Access
- 1 June 2008
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 4 (3) , 547-552
Abstract
Early vascular aging (EVA): consequences and prevention Peter M NilssonDepartment of Clinical Sciences Medicine, Lund University, University Hospital, Malmö, Sweden It has often been recognized that a discrepancy exists during the clinical consultation between the chronological age of a patient on the one hand with the signs and symptoms of biological age that can be recorded on the other hand. In cardiovascular medicine this is obvious when a heavy smoker presents with features of early biological aging, for example skin appearance and impaired lung function. This could also be extrapolated to vascular function as the target for numerous cardiovascular risk factors, thereby increasing the risk of early cardiovascular disease (CVD). Both new and old treatment modalities can play a role for the prevention of early vascular aging, first of all smoking cessation and improved lifestyle in general, but later on also the use of drugs such as statins or agents that block the renin – angiotensin system (RAS). New classes of drugs are currently being tested for CVD prevention, including glitazones and rimonabant, even if adverse effects (heart failure and depression) might restrict their usefulness. Results from ongoing intervention studies will eventually cast new light on possibilities to prevent the development of vascular aging.Keywords: aging, cardiovascular, diabetes, hypertension, risk factor, smoking, vascularKeywords
This publication has 60 references indexed in Scilit:
- Biological ageing: A fundamental, biological link between socio-economic status and health?European Journal of Public Health, 2004
- Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trialsAmerican Heart Journal, 2004
- Telomere Shortening in Human Coronary Artery DiseasesArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Short Telomeres Are Associated With Increased Carotid Atherosclerosis in Hypertensive SubjectsHypertension, 2004
- Family burden of cardiovascular mortality: risk implications for offspring in a national register linkage study based upon the Malmö Preventive ProjectJournal of Internal Medicine, 2004
- Adverse social factors predict early ageing in middle-aged men and women: the Ebeltoft Health Study, DenmarkScandinavian Journal of Public Health, 2003
- Growth, telomere dynamics and successful and unsuccessful human agingMechanisms of Ageing and Development, 2003
- Social factors and increase in mortality in Russia in the 1990s: prospective cohort studyBMJ, 2003
- Socioeconomic factors and cardiovascular disease: a review of the literature.Circulation, 1993
- Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention TrialDiabetes Care, 1993